The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the JDRF T1D Fund, startups are often financed by Vatera Healthcare Partners, Visionnaire Ventures, Senvest Capital. The meaningful sponsors for the fund in investment in the same round are Visionnaire Ventures, Senvest Capital, Quadrant Capital Advisors. In the next rounds fund is usually obtained by Viva Ventures Biotech Group, Visionnaire Ventures, Total Access Fund.
The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2019. The real fund results show that this VC is 18 percentage points more often commits exit comparing to other companies. The fund is constantly included in 2-6 deals per year. Comparing to the other companies, this JDRF T1D Fund performs on 21 percentage points less the average number of lead investments. The important activity for fund was in 2017.
The overall number of key employees were 4.
Among the most successful fund investment fields, there are Biotechnology, Health Care. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Diasome, ImmusanT, Bigfoot Biomedical. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low.
Related Funds
| Fund Name | Location |
| Bangkok bank | Bangkok, Krung Thep, Thailand |
| Infore Group | China, Foshan, Guangdong Province |
| Lafayette General Hospital | Lafayette, Louisiana, United States |
| Lululemon | British Columbia, Canada, Vancouver |
| LVL1 Group | Cyprus, Limassol, Limassol |
| Optical Capital Group | Columbia, Maryland, United States |
| Shanghai U9 Game | China, Shanghai |
| Silicon Valley Huoju Fund | - |
| SMD MedicalTrade | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Cour Pharmaceuticals Development | $105M | 30 Jan 2024 | Elmhurst, Illinois, United States | ||
DiogenX | $39M | 10 May 2023 | Marseille, Provence-Alpes-Côte d'Azur, France | ||
Inversago Pharma | $75M | 17 Oct 2022 | Montreal, Quebec, Canada | ||
Code Biotherapeutics | $75M | 07 Jun 2022 | Hatfield, Pennsylvania, United States | ||
Kriya Therapeutics | $270M | 16 May 2022 | Palo Alto, California, United States | ||
Biolinq | $100M | 02 Nov 2021 | San Diego, California, United States | ||
GentiBio | $157M | 11 Aug 2021 | Seattle, Washington, United States | ||
Sonoma BioTherapeutics | $265M | 04 Aug 2021 | South San Francisco, California, United States | ||
Kriya Therapeutics | $100M | 14 Jul 2021 | Palo Alto, California, United States |
– GentiBio, Inc. from Boston develops engineered regulatory T cells (Tregs) therapies for immunology.
– Series A $157m round was led by Matrix Capital Management with participation from Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management, and Novartis Venture Fund.
– The company intends to use the funds to advance its potential functional cure for Type 1 Diabetes (T1D) to the clinic alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation.
– Kriya closed a $100m Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies.
– The financing was led by Patient Square Capital with participation from new investors Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others.
– All existing institutional investors also participated in this round, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF T1D Fund.
– Proceeds from the financing will be used to further develop Kriya’s core technology platforms, expand its therapeutic pipeline and advance its current programs in metabolic disease, ophthalmology and oncology.
– Jim Momtazee, Managing Partner of Patient Square Capital, will join Kriya’s Board of Directors.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Cour Pharmaceuticals Development | $105M | 30 Jan 2024 | Elmhurst, Illinois, United States | ||
DiogenX | $39M | 10 May 2023 | Marseille, Provence-Alpes-Côte d'Azur, France | ||
Inversago Pharma | $75M | 17 Oct 2022 | Montreal, Quebec, Canada | ||
Code Biotherapeutics | $75M | 07 Jun 2022 | Hatfield, Pennsylvania, United States | ||
Kriya Therapeutics | $270M | 16 May 2022 | Palo Alto, California, United States | ||
Biolinq | $100M | 02 Nov 2021 | San Diego, California, United States | ||
GentiBio | $157M | 11 Aug 2021 | Seattle, Washington, United States | ||
Sonoma BioTherapeutics | $265M | 04 Aug 2021 | South San Francisco, California, United States | ||
Kriya Therapeutics | $100M | 14 Jul 2021 | Palo Alto, California, United States |
